GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adaptimmune Therapeutics PLC (STU:473A) » Definitions » Issuance of Stock

Adaptimmune Therapeutics (STU:473A) Issuance of Stock : €26.8 Mil (TTM As of Dec. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Adaptimmune Therapeutics Issuance of Stock?

Adaptimmune Therapeutics's Issuance of Stock for the three months ended in Dec. 2024 was €0.0 Mil.

Adaptimmune Therapeutics's Issuance of Stock for the trailing twelve months (TTM) ended in Dec. 2024 was €26.8 Mil.


Adaptimmune Therapeutics Issuance of Stock Historical Data

The historical data trend for Adaptimmune Therapeutics's Issuance of Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adaptimmune Therapeutics Issuance of Stock Chart

Adaptimmune Therapeutics Annual Data
Trend Jun15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Issuance of Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 274.87 2.24 12.10 0.57 27.86

Adaptimmune Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Issuance of Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 26.83 0.01 - -

Adaptimmune Therapeutics Issuance of Stock Calculation

A company may raise cash from issuing new shares. Issuance of Stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Issuance of Stock for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €26.8 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Adaptimmune Therapeutics Issuance of Stock Related Terms

Thank you for viewing the detailed overview of Adaptimmune Therapeutics's Issuance of Stock provided by GuruFocus.com. Please click on the following links to see related term pages.


Adaptimmune Therapeutics Business Description

Traded in Other Exchanges
Address
60 Jubilee Avenue, Milton Park, Abingdon, Oxfordshire, GBR, OX14 4RY
Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70, and others for multiple cancer types.

Adaptimmune Therapeutics Headlines

No Headlines